Technology wins partial victory in UK inhaled delivery appraisal
This article was originally published in Clinica
Executive Summary
Technological benefits have partially overridden cost considerations in a revised version of draft guidance issued today by the UK's National Institute for Health and Clinical Excellence (NICE) on the inhaled delivery of insulin for the treatment of diabetes (types 1 and 2).